The controlled multi-centre, randomised, prospective trial is investigating the therapy in kidney transplant recipients.

Post Marketing Study to Evaluate the Role of CYTOGAM in the Reduction of Risk of Late CMV Disease Following the Conclusion of ...

CAMBRIDGE, MA / ACCESS Newswire / October 22, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the Company’s ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients will continue.

Investing.com -- Moderna Inc. (NASDAQ:MRNA) stock fell 5% in after-hours trading Wednesday following the company’s announcement that its cytomegalovirus (CMV) vaccine candidate failed to meet its ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women from the virus in a large phase 3 trial, the biotech announced in a ...

Risk factors for cytomegalovirus infection among adults with rheumatic musculoskeletal diseases included diabetes, prior malignancy, intravenous cyclophosphamide, and an initial prednisolone dose ...

Sept 29 (Reuters) - Enanta Pharmaceuticals (ENTA.O), opens new tab said its experimental respiratory syncytial virus treatment significantly quickened recovery in a mid-stage study of adults at high ...